Bibliographie : Kétamine Dr Christian Sueur, GRECC, (mai 2021) Kétamine en Psychiatrie : 1 - 3 Usages thérapeutiques en médecine psychédélique : 4 Kétamine et psychose : 5 - 6 Kétamine et traitement de la dépression : 7 - 20 Kétamine et prise en charge de l’idéation suicidaire : 21 - 22 Kétamine et traitement de la dépression chez les enfants et adolescents : 23 - 24 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) : 25 - 27 Ketamine et addictions : 28 - 29 Kétamine et sevrage des opiacés : 30 Kétamine et prise en charge de la douleur : 31 - 32 Kétamine et prise en charge de [...]
Lire la suiteMDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]
Lire la suiteThe Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159 Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]
Lire la suiteRepeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]
Lire la suiteReviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/ Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]
Lire la suitePTSD as a mediator of the relationship between trauma and psychotic experiences Daniela Strelchuk, Gemma Hammerton, Nicola Wiles, Jazz Croft, Katrina Turner, Jonathan Heron and Stanley Zammit Psychological Medicine, 2020, 1–9. doi : 10.1017/S0033291720004821 Abstract Background : Traumatic experiences are associated with a higher risk of psychotic illnesses, but little is known about potentially modifiable mechanisms underlying this relationship. This study aims to examine whether post-traumatic stress disorder (PTSD) symptoms mediate the relationship between trauma and psychotic experiences (PEs). Methods : We used data from the Avon Longitudinal Study of Parents and Children to examine whether: PTSD symptoms mediate the relationships between (a) childhood trauma and [...]
Lire la suiteMind Menders: The Future of Psychedelics for Mental Illness Batya Swift Yasgur MA, LSW Medscape.com, November 10, 2020 https://www.medscape.com/viewarticle/940749?nlid=138288_425&src=WNL_mdplsfeat_201117_mscpedit_psyc&uac=292598PZ&spon=12&impID=2682236&faf=1 After a 50-year hiatus, psychedelic drugs are undergoing a research renaissance. Agents including psilocybin, methylenedioxymethamphetamine (MDMA), and others are all under investigation to treat a variety of psychiatric illnesses. Medscape spoke with Roland R. Griffiths, professor in the Departments of Psychiatry and Neuroscience and the Oliver Lee McCabe III Professor in the Neuropsychopharmacology of Consciousness, and director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University, Baltimore, Maryland, to discuss the status of these drugs in the United States and their therapeutic potential. Griffiths: Classic psychedelics are [...]
Lire la suiteDevelopment of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01 ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]
Lire la suiteBenefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review Maya E. O’Neil, PhD; Shannon M. Nugent, PhD; Benjamin J. Morasco, PhD; Michele Freeman, MPH; Allison Low, BA; Karli Kondo, PhD; Bernadette Zakher, MBBS; Camille Elven, MD; Makalapua Motu’apuaka, BA; Robin Paynter, MLIS; and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020 doi : 10.7326/M17-0477 Background : Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose : To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based [...]
Lire la suiteShort and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132 A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]
Lire la suite